To our knowledge, only one gene therapy drug, Luxturna®, has been approved to date for RPE65-associated LCA, which is associated with mutations in the RPE65 gene encoding retinoid isomerohydrolase in the retinal pigment epithelium, leading to rod-type retinal dystrophy [188]. Here, RPE65 is linked to Leber congenital amaurosis.